|
Wednesday, August 15, 2007 8:00am — IP WARS, PHARMA, BIOTECH & CHEM IP STRATEGY, GLOBAL IP STRATEGY US / China TRIPS case goes to WTO panel - what about India?On Monday, the US Trade Representative requested establishment of a WTO dispute resolution panel to deal with its case challenging alleged deficiencies in Chinese intellectual property law. A quote from the USTR's press release: “In pursuing this action, the United States is seeking to eliminate significant structural deficiencies that give pirates and counterfeiters in China a safe harbor to avoid criminal liability. The United States is also seeking to improve enforcement procedures at China's border, and to give copyright owners more tools to prevent the production of unauthorized copies in China." The U.S. is alleging 3 violations of TRIPS (copy of the TRIPS agreement here):
This is one of five WTO cases the United States has brought against China and the third case in which the U.S. has requested has requested a WTO dispute settlement panel. (More background at IP Dragon.) The Novartis Glivec dispute (see also IP ThinkTank discussion) has highlighted another potential WTO TRIPS dispute, this time in relation to India and patents. The pressure to do this has been increased by Tuesday''s Times of India article which suggests that the Indian Patent Act is a role model for other nations. The question for Pharmaceutical lobby groups (such as PhRMA) then, is whether to put pressure on politicians in the U.S. or elsewhere to take a similar stance against India in relation to India's section 3(d). A threshold question before that, is of course, do they have a case? What do you think? Post a Comment | Permalink | + del.icio.us 0 Comments0 Trackbackstrackback url: http://duncanbucknell.com/trackback.php?id=115 |
|


















